Report
EUR 14.00 For Business Accounts Only

CONMED suffers a double requalification, which weighs heavily on its rating, now at Neutral.

The independent financial analyst theScreener just downgraded the general evaluation of CONMED (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Neutral. As of the analysis date November 19, 2021, the closing price was USD 142.01 and its target price was estimated at USD 124.71.
Underlying
CONMED Corporation

CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The company's product lines consist of orthopedic surgery, which consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments, as well as imaging systems for use in minimally invasive surgery procedures and service fees related to the promotion and marketing of sports medicine allograft tissue; and general surgery, which consists of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, cardiac monitoring products as well as electrosurgical generators and related instruments.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch